Shin Nippon Biomedical Laboratories (YB3) Stock Overview
A contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
YB3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Shin Nippon Biomedical Laboratories, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥8.20 |
| 52 Week High | JP¥11.50 |
| 52 Week Low | JP¥6.25 |
| Beta | -0.33 |
| 1 Month Change | 7.89% |
| 3 Month Change | -4.09% |
| 1 Year Change | 10.81% |
| 3 Year Change | -45.70% |
| 5 Year Change | 62.38% |
| Change since IPO | -34.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| YB3 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -0.6% | -2.7% | 2.8% |
| 1Y | 10.8% | -16.4% | 19.3% |
Return vs Industry: YB3 exceeded the German Life Sciences industry which returned -14.7% over the past year.
Return vs Market: YB3 underperformed the German Market which returned 19.1% over the past year.
Price Volatility
| YB3 volatility | |
|---|---|
| YB3 Average Weekly Movement | 7.0% |
| Life Sciences Industry Average Movement | 6.5% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: YB3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: YB3's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 1,436 | Ryoichi Nagata | www.snbl.co.jp |
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally. It offers non-clinical studies, including single/repeated dose toxicity studies, antigenicity studies, skin sensitization studies, genotoxicity studies, carcinogenicity studies, local irritation studies, inhalation toxicity studies, TK studies, characteristic studies, stability studies, dependence studies, reproductive and developmental toxicity studies, safety pharmacological studies, and pharmacokinetic studies. The company also engages in the investigator brochure preparation support, clinical trial protocol creation support, clinical trial medical institution, investigational drug allocation, clinical trial request/contract, monitoring, quality management, data management, statistical analysis work, comprehensive report creation support, electronic application support, regulatory affairs consulting, and creating informed consent documents support services.
Shin Nippon Biomedical Laboratories, Ltd. Fundamentals Summary
| YB3 fundamental statistics | |
|---|---|
| Market cap | €341.03m |
| Earnings (TTM) | €28.71m |
| Revenue (TTM) | €188.98m |
Is YB3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YB3 income statement (TTM) | |
|---|---|
| Revenue | JP¥32.41b |
| Cost of Revenue | JP¥15.45b |
| Gross Profit | JP¥16.96b |
| Other Expenses | JP¥12.04b |
| Earnings | JP¥4.92b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 05, 2025
| Earnings per share (EPS) | 118.27 |
| Gross Margin | 52.32% |
| Net Profit Margin | 15.19% |
| Debt/Equity Ratio | 84.9% |
How did YB3 perform over the long term?
See historical performance and comparisonDividends
Does YB3 pay a reliable dividends?
See YB3 dividend history and benchmarks| Shin Nippon Biomedical Laboratories dividend dates | |
|---|---|
| Ex Dividend Date | Sep 29 2025 |
| Dividend Pay Date | Dec 01 2025 |
| Days until Ex dividend | 81 days |
| Days until Dividend pay date | 144 days |
Does YB3 pay a reliable dividends?
See YB3 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/09 06:41 |
| End of Day Share Price | 2025/07/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shin Nippon Biomedical Laboratories, Ltd. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuki Tsukamoto | BofA Global Research |
| Akitada Iwasa | Daiwa Securities Co. Ltd. |
| Stephen Barker | Jefferies LLC |